AMGN · News · 20260911N
MariTide Pipeline Progress
AMGEN INC · 2026-09-11 · Importance 31 · Surprise 42 · In source text
Amgen highlighted MariTide’s potential in obesity and related conditions, with a differentiated dosing schedule and substantial weight loss reported in a Phase II study. The company also identified possible cardiovascular benefits, which could expand the drug’s addressable market beyond weight management. Phase III studies are underway across multiple indications, creating a material future development and commercialization opportunity.
Key facts
- Amgen said Phase III studies for MariTide are underway for various indications. source
- Amgen reported MariTide produced substantial weight loss in Phase II. source
- Amgen described MariTide as having a differentiated dosing schedule. source
- Amgen noted MariTide has possible cardiovascular benefits. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Amgen said Phase III studies for MariTide are underway for various indications. |